{"certainAgreement":{"otherDetails":"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:\n\n* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or\n* The study has been completed at all study sites for at least 2 years","piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true},"limitationsAndCaveats":{"description":"This study was terminated early due to the Sponsor's decision to discontinue development of the investigational drug and program closure. Due to early termination of the study, reported findings should be interpreted in the context of the study's early closure."},"pointOfContact":{"email":"GileadClinicalTrials@gilead.com","organization":"Gilead Sciences","phone":"1-833-445-3230 (GILEAD-0)","title":"Gilead Clinical Study Information Center"}}